Bellicum Pharma (BLCM) Tops Q4 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall St mixed as Middle East tensions eclipse tech strength
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
Bellicum Pharmaceuticals (BLCM) PT Lowered to $25 at Citi Following Rimiducid Activation Switch
March 15, 2018 6:58 AM EDTCiti lowered its price target on Bellicum Pharmaceuticals (NASDAQ: BLCM) to $25.00 (from $27.00) while maintaining a Buy rating following the company's announced details of the first patient to receive the Rimiducid activation switch. The company is still investigating what happened to the cells, and noted... More
